Madrigal Pharmaceuticals, Inc. MDGL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.13B+257% | $958.4M+432% | $740.64M+864% | $515.55M+3,422% | $317.38M— | ||
| —— | —— | —— | —— | —— | ||
| $453.05M+116% | $388.53M+64.1% | $297.91M+5.7% | $192.64M-32.1% | $209.65M-25.5% | ||
| $914.47M+75.1% | $813.83M+87.1% | $715.07M+110% | $613.54M+136% | $522.13M+202% | ||
| $1.45B+94.7% | $1.26B+85.6% | $1.05B+67.7% | $825.36M+51.5% | $742.53M+63.5% | ||
| $78.48M-88.5% | $56.15M-91.7% | $706.92M+84.4% | $690.95M+81.3% | $682.52M+79.4% | ||
| -$313.51M+26.3% | -$300.1M+39.7% | -$307.48M+43.9% | -$309.81M+41.6% | -$425.15M+6.4% | ||
| -27.7%+106pp | -31.3%+245pp | -41.5%+672pp | -60.1%+3,563pp | -134%— | ||
| $26.83M+89.9% | $22.31M+52.1% | $17.51M+15.6% | $13.74M-8.2% | $14.13M-0.6% | ||
| -$2.56M— | -$463K— | -$335K— | -$42K— | $0— | ||
| -$309.44M+21.0% | -$288.28M+38.1% | -$289.13M+44.3% | -$281.9M+44.8% | -$391.59M+11.9% | ||
| -27.3%+96.1pp | -30.1%+229pp | -39%+636pp | -54.7%+3,432pp | -123.4%— | ||
| -$10.79— | -$10.15— | —— | —— | —— | ||
| -$312M+26.4% | -$298.59M+39.9% | -$306.01M+44.1% | -$308.4M+41.8% | -$423.84M+6.6% | ||
| -27.5%+106pp | -31.2%+245pp | -41.3%+671pp | -59.8%+3,558pp | -133.5%— | ||
| -$313.51M+26.3% | -$300.1M+39.7% | -$307.48M+43.9% | -$309.81M+41.6% | -$425.15M+6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) generated $1.1B in revenue over the trailing twelve months, up 256.8% year over year.
- Is Madrigal Pharmaceuticals, Inc. profitable?
- Madrigal Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $309.4M over the trailing twelve months, a -27.3% net margin.
- What are Madrigal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 96.5% and operating margin is -27.7%, with a -27.3% net margin.
- What is Madrigal Pharmaceuticals, Inc.'s earnings per share?
- Madrigal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-10.79.
- Where does Madrigal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
